The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer

Biomedicine and Pharmacotherapy

Volumn 88, Issue , 2017, Pages 302-308

  Huang, Tao ^a   Liu, Hong Wei ^b   Chen, Jia Qi ^b   Wang, Shou Han ^b   Hao, Li Qun ^b   Liu, Miao ^b   Wang, Bin ^b  

^a CHANGCHUN UNIVERSITY OF CHINESE MEDICINE   (China)

^b Jilin Province Tumor Hospital   (China)

Author keywords

Cell proliferation; Gastric cancer; miR 186; Plasmacytoma variant translocation 1

Indexed keywords

CYCLINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LONG UNTRANSLATED RNA; LONG UNTRANSLATED RNA PLASMACYTOMA VARIANT TRANSLOCATION 1; MICRORNA; MICRORNA 186; UNCLASSIFIED DRUG; MIRN186 MICRORNA, HUMAN; PVT1 LONG-NON-CODING RNA, HUMAN; RNA;

ADULT; ARTICLE; BINDING SITE; CANCER STAGING; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; STOMACH CARCINOGENESIS; UPREGULATION; WESTERN BLOTTING; AGED; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; LYMPHATIC METASTASIS; MIDDLE AGED; PREVENTION AND CONTROL; STOMACH NEOPLASMS; TUMOR CELL LINE; TUMOR INVASION;

ADULT; AGED; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; RNA, LONG NONCODING; RNA, NEOPLASM; STOMACH NEOPLASMS;

EID: 85009902103     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.01.049     Document Type: Article

References (27)

1. [1] Baniak, N., Senger, J.L., Ahmed, S., Kanthan, S.C., Kanthan, R., Gastric biomarkers: a global review. World J. Surg. Oncol., 14, 2016, 212.
2. [2] Sun, W., Yan, L., Gastric cancer: current and evolving treatment landscape. Chin. J. Cancer, 35, 2016, 83.
3. [3] Kanat, O., O'Neil, B.H., Metastatic gastric cancer treatment: a little slow but worthy progress. Med. Oncol., 30, 2013, 464.
4. [4] Grillo, F., Fassan, M., Sarocchi, F., Fiocca, R., Mastracci, L., HER2 heterogeneity in gastric/gastroesophageal cancers: from benchside to practice. World J. Gastroenterol. 22 (2016), 5879–5887.
5. [5] Fang, X.Y., Pan, H.F., Leng, R.X., Ye, D.Q., Long noncoding RNAs: novel insights into gastric cancer. Cancer Lett. 356 (2015), 357–366.
6. [6] Zhao, J., Liu, Y., Huang, G., Cui, P., Zhang, W., Zhang, Y., Long non-coding RNAs in gastric cancer: versatile mechanisms and potential for clinical translation. Am. J. Cancer Res. 5 (2015), 907–927.
7. [7] Li, H., Yu, B., Li, J., Su, L., Yan, M., Zhu, Z., Liu, B., Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 5 (2014), 2318–2329.
8. [8] Zhang, E.B., Kong, R., Yin, D.D., You, L.H., Sun, M., Han, L., Xu, T.P., Xia, R., Yang, J.S., De, W., Chen, J.F., Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 5 (2014), 2276–2292.
9. [9] Peng, W., Wu, G., Fan, H., Wu, J., Feng, J., Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer. Tumour Biol. 36 (2015), 6751–6758.
10. [10] Takahashi, Y., Sawada, G., Kurashige, J., Uchi, R., Matsumura, T., Ueo, H., Takano, Y., Eguchi, H., Sudo, T., Sugimachi, K., Yamamoto, H., Doki, Y., Mori, M., Mimori, K., Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br. J. Cancer 110 (2014), 164–171.
11. [11] Guan, Y., Kuo, W.L., Stilwell, J.L., Takano, H., Lapuk, A.V., Fridlyand, J., Mao, J.H., Yu, M., Miller, M.A., Santos, J.L., Kalloger, S.E., Carlson, J.W., Ginzinger, D.G., Celniker, S.E., Mills, G.B., Huntsman, D.G., Gray, J.W., Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin. Cancer Res. 13 (2007), 5745–5755.
12. [12] Wan, L., Sun, M., Liu, G.J., Wei, C.C., Zhang, E.B., Kong, R., Xu, T.P., Huang, M.D., Wang, Z.X., Long noncoding RNA PVT1 promotes non-Small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression. Mol. Cancer Ther. 15 (2016), 1082–1094.
13. [13] Kong, R., Zhang, E.B., Yin, D.D., You, L.H., Xu, T.P., Chen, W.M., Xia, R., Wan, L., Sun, M., Wang, Z.X., De, W., Zhang, Z.H., Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol. Cancer, 14, 2015, 82.
14. [14] Katoh, M., Katoh, M., Integrative genomic analyses of ZEB2: transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1alpha, POU/OCT, and NF-kappaB. Int. J. Oncol. 34 (2009), 1737–1742.
15. [15] Tanaka, T., Kitajima, Y., Miyake, S., Yanagihara, K., Hara, H., Nishijima-Matsunobu, A., Baba, K., Shida, M., Wakiyama, K., Nakamura, J., Noshiro, H., The apoptotic effect of HIF-1alpha inhibition combined with glucose plus insulin treatment on gastric cancer under hypoxic conditions. PLoS One, 10, 2015, e0137257.
16. [16] Mercer, T.R., Dinger, M.E., Mattick, J.S., Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10 (2009), 155–159.
17. [17] Iden, M., Fye, S., Li, K., Chowdhury, T., Ramchandran, R., Rader, J.S., The lncRNA PVT1 contributes to the cervical cancer phenotype and associates with poor patient prognosis. PLoS One, 11, 2016, e0156274.
18. [18] Liu, E., Liu, Z., Zhou, Y., Mi, R., Wang, D., Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int. J. Clin. Exp. Med. 8 (2015), 20565–20572.
19. [19] Liz, J., Esteller, M., lncRNAs and microRNAs with a role in cancer development. Biochim. Biophys. Acta 1859 (2016), 169–176.
20. [20] Li, J., Wang, J., Chen, Y., Li, S., Jin, M., Wang, H., Chen, Z., Yu, W., LncRNA MALAT1 exerts oncogenic functions in lung adenocarcinoma by targeting miR-204. Am. J. Cancer Res. 6 (2016), 1099–1107.
21. [21] Wang, S.H., Wu, X.C., Zhang, M.D., Weng, M.Z., Zhou, D., Quan, Z.W., Long noncoding RNA H19 contributes to gallbladder cancer cell proliferation by modulated miR-194-5p targeting AKT2. Tumour Biol. 37 (2016), 9721–9730.
22. [22] Xu, C., Shao, Y., Xia, T., Yang, Y., Dai, J., Luo, L., Zhang, X., Sun, W., Song, H., Xiao, B., Guo, J., lncRNA-AC130710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis. Tumour Biol. 35 (2014), 9701–9706.
23. [23] Zheng, J., Yu, F., Dong, P., Wu, L., Zhang, Y., Hu, Y., Zheng, L., Long non-coding RNA PVT1 activates hepatic stellate cells through competitively binding microRNA-152. Oncotarget 7 (2016), 62886–62897.
24. [24] Semenza, G.L., HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8 (2002), S62–67.
25. [25] Wang, J., Ni, Z., Duan, Z., Wang, G., Li, F., Altered expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and its regulatory genes in gastric cancer tissues. PLoS One, 9, 2014, e99835.
26. [26] Chen, L., Shi, Y., Yuan, J., Han, Y., Qin, R., Wu, Q., Jia, B., Wei, B., Wei, L., Dai, G., Jiao, S., HIF-1 alpha overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients post-gastrectomy. PLoS One, 9, 2014, e90678.
27. [27] Liu, H.L., Liu, D., Ding, G.R., Liao, P.F., Zhang, J.W., Hypoxia-inducible factor-1alpha and Wnt/beta-catenin signaling pathways promote the invasion of hypoxic gastric cancer cells. Mol. Med. Rep. 12 (2015), 3365–3373.